Passage Bio
Founded 2017 · CIK 0001787297 · Biotech · Public
Gene therapies for severe monogenic CNS disorders
passagebio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $110M
- 1 Form D · Sep 2019
- 85 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 0 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $109,999,974 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2817 | LYST THERAPEUTICS LLC | — | — |
| 2818 | Relation Therapeutics | — | $116M |
| 2819 | STEL Technologies, LLC | — | — |
| 2820 | Passage Bio | — | $110M |
| 2821 | Acadia Pharmaceuticals | — | $107M |
| 2822 | Neurogene Inc. | — | $106M |
| 2823 | Ovid Therapeutics | — | $106M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Carl GordonDirector
- Patrick HeronDirector
- Saqib IslamDirector
- Stephen SquintoDirector · Executive Officer
- Thomas Street Address 1 WoiwodeDirector
- Tadataka YamadaDirector · Executive Officer · Promoter
Patents
- Method Of Purifying Full Recombinant Aav Particlesapplication
- Recombinant Adeno-associated Virus For Treatment Of Neurodegenerative Disordersapplication
- Recombinant Adeno-Associated Virus for Treatment of Neurodegenerative Disordersapplication
- Recombinant Adeno-Associated Virus for Treatment of Neurodegenerative Disordersapplication
- Recombinant Adeno-Associated Virus for Treatment of Neurodegenerative Disordersapplication
- Potency Assay Of Progranulinapplication
- Recombinant Adeno-associated Virus For Treatment Of Neurodegenerative Disordersapplication
- Method Of Purifying Full Recombinant Aav Particlesapplication
- Potency Assay Of Progranulinapplication
- Method Of Purifying Full Recombinant Aav Particlesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.